How many 8-K filings has Sutro Biopharma, Inc. filed?

Sutro Biopharma, Inc. (STRO) has 14 8-K (Current Event Report) filings on record, spanning Jan 2024 to Mar 2026.

What is a 8-K filing?

A 8-K is an SEC filing known as "Current Event Report." Filed to announce significant events or material changes such as acquisitions, executive departures, earnings announcements, or bankruptcy filings.

Where can I read Sutro Biopharma, Inc. 8-K filings in plain English?

ReadTheFiling provides AI-powered plain-English summaries of all Sutro Biopharma, Inc. 8-K filings, including risk assessment, sentiment analysis, and key financial figures.

Sutro Biopharma, Inc. (STRO) — 8-K Filings

All 8-K filings from Sutro Biopharma, Inc.. Browse 14 Current Event Report reports with AI-powered summaries and risk analysis.

8-K Filings (14)

Sutro Biopharma Terminates Material Agreement, Discloses Financials — Mar 23, 2026
Sutro Biopharma, Inc. filed an 8-K on March 23, 2026, announcing the termination of a material definitive agreement under Item 1.02 and disclosing results of op
Sutro Biopharma Files 8-K — Dec 17, 2025 Risk: medium
Sutro Biopharma, Inc. filed an 8-K on December 17, 2025, reporting an 'Other Event'. The filing does not contain specific details about the event, dollar amount
8-K Filing — Dec 3, 2025
Sutro Biopharma Reports Exit Costs and Files Exhibits — Sep 29, 2025 Risk: medium
On September 29, 2025, Sutro Biopharma, Inc. filed an 8-K report detailing cost associated with exit or disposal activities. The filing also included financial
Sutro Biopharma Faces Nasdaq Delisting Warning — Jun 25, 2025 Risk: high
Sutro Biopharma, Inc. announced on June 20, 2025, that it received a notice from the Nasdaq Stock Market regarding its failure to meet the minimum bid price req
Sutro Biopharma Reports on Shareholder Vote Matters — Jun 10, 2025 Risk: low
Sutro Biopharma, Inc. filed an 8-K on June 10, 2025, reporting on matters submitted to a vote of security holders on June 6, 2025. The filing details the compan
Sutro Biopharma Appoints New CMO, CFO, and Director — Jun 2, 2025 Risk: medium
Sutro Biopharma, Inc. announced on June 2, 2025, changes in its executive team and board. Dr. William D. Young has been appointed as the new Chief Medical Offic
Sutro Biopharma Announces Executive and Director Changes — Apr 14, 2025 Risk: medium
On April 10, 2025, Sutro Biopharma, Inc. announced changes in its executive and director roles. Dr. William Newell was appointed as Chief Medical Officer, and M
Sutro Biopharma Files 8-K — Dec 10, 2024 Risk: low
On December 10, 2024, Sutro Biopharma, Inc. filed an 8-K report. The filing does not contain specific details about events, financial figures, or material chang
Sutro Biopharma Appoints New CMO, Adds Director — Aug 12, 2024 Risk: low
Sutro Biopharma, Inc. announced on August 8, 2024, the appointment of Dr. William Newell as Chief Medical Officer and the election of Dr. Pamela L. Wagner to it
Sutro Biopharma Reports Shareholder Vote Matters — Jun 10, 2024 Risk: low
Sutro Biopharma, Inc. filed an 8-K on June 10, 2024, reporting on matters submitted to a vote of security holders as of June 6, 2024. The filing does not detail
Sutro Biopharma Files 8-K: Material Agreement & Equity Sales — Apr 2, 2024 Risk: medium
On March 29, 2024, Sutro Biopharma, Inc. entered into a material definitive agreement. The company also disclosed unregistered sales of equity securities and pr
Sutro Biopharma Files 8-K for 'Other Events' & Exhibits — Feb 9, 2024 Risk: medium
Sutro Biopharma, Inc. filed an 8-K on February 9, 2024, to report an 'Other Event' and 'Financial Statements and Exhibits'. This filing indicates that the compa
Sutro Biopharma Confirms Non-Emerging Growth Company Status — Jan 8, 2024
Sutro Biopharma, Inc. filed an 8-K on January 8, 2024, reporting an event on January 4, 2024. This filing indicates that Sutro Biopharma, Inc. is not an emergin

Popular Companies

AAPL · TSLA · MSFT · AMZN · GOOGL · META · NVDA · JPM · BRK-B · V · JNJ · UNH · XOM · WMT · MA · PG · HD · DIS · BAC · NFLX